Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Saved in:
Bibliographic Details
Title: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Authors: Chan A; Breast Cancer Research Centre-Western Australia and Curtin University, Perth, WA, Australia. Electronic address: arlenechan@me.com., Delaloge S; Institut Gustave Roussy, Villejuif, France., Holmes FA; Texas Oncology, Houston, TX, USA., Moy B; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Iwata H; Aichi Cancer Center, Chikusa-ku, Nagoya, Japan., Harvey VJ; Auckland Hospital, Auckland, New Zealand., Robert NJ; Virginia Cancer Specialists, The US Oncology Network, Fairfax, VA, USA., Silovski T; University Hospital For Tumors, University Hospital Center 'Sestre Milosrdnice', Zagreb, Croatia., Gokmen E; Ege University Faculty of Medicine, Izmir, Turkey., von Minckwitz G; Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-lsenburg, Germany., Ejlertsen B; Rigshospitalet, Copenhagen, Denmark., Chia SKL; BC Cancer Agency, Vancouver, BC, Canada., Mansi J; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, UK., Barrios CH; Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil., Gnant M; Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria., Buyse M; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium., Gore I; Alabama Oncology, Birmingham, AL, USA., Smith J 2nd; Northwest Cancer Specialists, Vancouver, VA, USA., Harker G; Utah Cancer Specialists, Salt Lake City, UT, USA., Masuda N; National Hospital Organization Osaka National Hospital, Chuou-ku, Osaka, Japan., Petrakova K; Masaryk Memorial Cancer Institute, Brno, Czech Republic., Zotano AG; Instituto Valenciano de Oncologia, València, Spain., Iannotti N; Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, FL, USA., Rodriguez G; South Texas Oncology and Hematology, San Antonio, TX, USA., Tassone P; Magna Graecia University, Catanzaro, Italy., Wong A; Puma Biotechnology, Los Angeles, CA, USA., Bryce R; Puma Biotechnology, Los Angeles, CA, USA., Ye Y; Puma Biotechnology, Los Angeles, CA, USA., Yao B; Puma Biotechnology, Los Angeles, CA, USA., Martin M; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
Corporate Authors: ExteNET Study Group
Source: The Lancet. Oncology [Lancet Oncol] 2016 Mar; Vol. 17 (3), pp. 367-377. Date of Electronic Publication: 2016 Feb 10.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(15)00551-3